Breaking Down the Disproportionate Burden of Kidney Disease Among African Populations

Kidney disease, leading to kidney failure, disproportionately affects black people compared to white people. This health disparity places a considerable financial and social burden on black communities worldwide.

In the United States, for instance, despite making up only 13% to 14% of the population, black individuals account for a staggering one-third of all patients with end-stage kidney disease requiring dialysis or transplantation.

Hypertension, diabetes, and HIV are key risk factors for kidney failure, but they appear to exacerbate kidney damage and lead to rapid disease progression more often in black people than in white individuals.

The Genetic Connection Behind Health Disparities

For decades, researchers have puzzled over the origins of these kidney disease disparities. It wasn’t until the last 15 years that scientists discovered a genetic variation protecting against trypanosomiasis, or sleeping sickness, a parasitic disease prevalent in West Africa.

This protective gene variant, producing a protein that destroys the parasite’s membrane, led to the evolution of resistant parasite strains. Newer gene variants emerged in response, restoring immunity but at a cost: increased risk of kidney disease.

Recent studies confirm that these variants contribute to kidney damage in African Americans, even without diabetes. However, the link between these genes and kidney disease has not been extensively explored among African populations where the variants originated.

The H3Africa Project: Unlocking New Insights

To address this gap, the Human Heredity and Health in Africa (H3Africa) project began over a decade ago. Its goal? Investigate and document kidney disease cases and genetic factors in sub-Saharan Africa.

The Kidney Disease Research Network assembled researchers from five countries to enroll 8,355 participants in Nigeria and Ghana, including 4,712 with kidney disease and 2,777 without.

Through extensive genetic studies, the team identified the presence of the APOL1 G1 and G2 variants—linked to kidney disease—in a significant portion of the study participants.

Key Findings: The APOL1 Gene and Chronic Kidney Disease in Africa

The study confirmed the critical role of the APOL1 gene in chronic kidney disease, a previously undocumented phenomenon in sub-Saharan Africa.

Research revealed that participants with double APOL1 G1 or G2 variants faced a higher risk of developing chronic kidney disease compared to those with single variants. Even individuals with a single variant experienced an increased risk.

These genetic findings align with earlier studies among African Americans, underscoring the global impact of the APOL1 gene and offering opportunities for targeted screening and treatment.

The Broader Implications

Understanding the genetic basis of kidney disease in African populations has several significant implications:

• Screening kidney transplant donors for high-risk APOL1 variants could improve patient outcomes.
• Developing targeted treatments for individuals with high-risk variants could alleviate the burden of kidney disease.

A drug called Inaxaplin, currently in development, has shown promise in reducing proteinuria, a key indicator of kidney disease, by inhibiting APOL1 function.

Current Kidney Disease Prevalence in Africa

According to recent studies, kidney disease prevalence is alarmingly high in some African countries. In Nigeria, the disease affects 13.7% of the population, while in Ghana, approximately 28% of individuals suffer from chronic kidney disease.

Addressing these health disparities is imperative for improving the quality of life and reducing the economic burden of kidney disease on African communities.

Conclusion: A Call for Action

The genetic origins of kidney disease disparities offer a clear path forward in addressing this critical public health challenge. By leveraging these insights, researchers, healthcare providers, and policymakers can develop targeted strategies to reduce the burden of kidney disease in African populations.

Through continued research, improved screening, and innovative treatments, we can make significant strides in mitigating the impact of chronic kidney disease on black people worldwide.

Join the conversation: Share your thoughts on this issue in the comments below, subscribe to our newsletter to receive updates, or follow us on social media for more insightful articles.